New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
08:20 EDTKINKindred Biosciences price target lowered to $19 from $30 at BMO Capital
BMO Capital cut its price target on Kindred after the company announced that its pivotal study of CereKin for the treatment of osteoarthritis in dogs did not meet its primary endpoint. However, the firm thinks that each of two other trials that the company is undertaking has a 70% chance of succeeding. The firm believes that the company has many more shots on goal, and it keeps an Outperform rating on the shares.
News For KIN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
19:00 EDTKINOn The Fly: After Hours Movers
Subscribe for More Information
16:08 EDTKINKindred Biosciences says Phase 2 study of KIND-012 meets primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use